SpringWorks Therapeutics (SWTX) Announces $225 Million Private Placement Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
SpringWorks Therapeutics Inc. (SWTX) to Resume Trading at 10:25 a.m.
September 7, 2022 10:04 AM EDTSpringWorks Therapeutics Inc. (NASDAQ: SWTX) to Resume Trading at 10:25 a.m.
... MoreSpringWorks Therapeutics (SWTX) Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
September 7, 2022 9:55 AM EDTSpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (LSE/NYSE: GSK) for nirogacestat, SpringWorks investigational oral gamma secretase inhibitor, in combination with Blenrep (belantamab mafodotin-blmf), GSKs antibody-drug conjugate targeting B-cell maturation antigen (BCMA).
Under the terms of the expanded agreement, SpringWorks will receive a $75 million equity investment from GSK, with shares of common... More
